Maria A. Raptis represents clients in connection with antitrust aspects of mergers and acquisitions, litigation, counseling and criminal matters.

Bio

Ms. Raptis concentrates her practice on representing clients before the Federal Trade Commission (FTC) and Department of Justice. She has advised clients in a broad range of strategic transactions across multiple industries, including, health care and pharmaceuticals, technology, consumer products, entertainment and manufacturing. Some of her significant representations include:

  • Xilinx, Inc. in its pending $35 billion acquisition by Advanced Micro Devices, Inc.;
  • Livongo Health in its pending $18.5 billion sale to Teladoc;
  • Visa Inc. in its pending $5.3 billion acquisition of Plaid Inc.;
  • ZeniMax Media Inc. in its pending $7.5 billion acquisition by Microsoft Corporation;
  • Array BioPharma in its $11.4 billion acquisition by Pfizer;
  • Gilead Sciences, Inc. in its $4.9 billion acquisition of Forty Seven and its $5.1 billion 10-year global research and development collaboration and equity investment in Galapagos NV, as well as its $11.9 billion acquisition of Kite Pharma, Inc. and $11 billion acquisition of Pharmasset;
  • PayPal in its $4 billion acquisition of Honey Science Corporation and its strategic investments in MercadoLibre, Inc. and Uber Technologies, Inc.;
  • Realogy Holdings Corp. in the proposed $400 million sale of its global Cartus Relocation business to SIRVA Worldwide, Inc.;
  • Achillion Pharmaceuticals, Inc. in its $930 million acquisition by Alexion Pharmaceuticals, Inc.;
  • First Bancorp. in its $1.1 billion acquisition of Banco Santander S.A.'s (Spain) Puerto Rico banking operations;
  • NXP Semiconductors N.V. in its proposed but terminated $47 billion acquisition by Qualcomm Incorporated;
  • Hewlett Packard Enterprise Co. in its $1.3 billion acquisition of Cray Inc. and its $1 billion acquisition of Samsung's printing business;
  • Intel Corporation in numerous transactions, including its $15.3 billion acquisition of Mobileye N.V. and its $1 billion sale of its modem business to Apple;
  • Airbnb in its $400 million acquisition of Hotel Tonight;
  • Carbonite, Inc. in its $1.4 billion acquisition by Open Text Corporation;
  • Sophos Group plc with U.S. aspects of its $3.9 billion acquisition by Thoma Bravo, LLC;
  • ArQule in its sale to Merck for $2.7 billion;
  • Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion;
  • TiVo Inc. in its $1.1 billion acquisition by Rovi Corporation;
  • SanDisk in its $19 billion acquisition by Western Digital;
  • Actavis in its $28 billion acquisition of Forest Laboratories and its $8.5 billion acquisition of Warner Chilcott;
  • Cineworld Group PLC in its $5.9 billion acquisition of Regal Entertainment Group;
  • Juno Therapeutics, Inc. in its $11 billion acquisition by Celgene Corporation;
  • Valeant in its acquisitions of Salix, Medicis, Dermik, Ortho Dermatologics and Biovail;
  • Watson in its $5.9 billion acquisition of Actavis and its $1.9 billion acquisition of Andrx; and
  • NDS Group in its $5 billion acquisition by Cisco Systems.

Ms. Raptis' litigation experience includes defending clients in connection with class actions and multidistrict litigations challenging patent settlements, pricing and other business policies, including Actavis in suits brought by the FTC and private plaintiffs relating to "reverse payment" settlements and De Beers in connection with national class actions involving gem diamonds.

Ms. Raptis also has represented clients in connection with allegations of price-fixing and other criminal charges, including De Beers in connection with the resolution of a criminal matter relating to industrial diamonds.

Credentials

Education

  • J.D., Columbia Law School, 2002
  • B.A., Columbia College, 1998

Admissions

  • New York

Maria Raptis

Partner, Antitrust/Competition
maria.raptis@skadden.com